| Trial ID # | NCT02498600; NRG-GY003 |
| Phase | II |
| Drug Class | Immunotherapy: Checkpoint Inhibitors/CTLA-4 |
| Drug Name | Ipilimumab |
| Alternate Drug Names | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy |
| Drugs in Trial | Ipilimumab, Nivolumab |
| Eligible Participant | Partially platinum sensitive, resistant or refractory ovarian cancer, 1-3 prior therapies, no prior immune checkpoint inhibitor |
| Patients Enrolled | 100; 62% Pt-R |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Randomized |
| Endpoints | ORR, PFS, OS, evaluated per RECIST |
| Efficacy | Ipi+Niv (n=51) vs Niv (n=49): ORR: 31.4 (3CR, 13PR) vs 12.2% (3CR, 3PR)(p=0.034) |
| Clinically Significant Adverse Events | Ipi+Niv vs Niv: |
| Conclusion | Encouraging anti-tumor activity of ipilimumab and nivolumab combination with favorable benefit over risk |
| Reference | Zamarin D et al. Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study. J Clin Oncol (2020) 38(16):1814-1823 |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.